peach state health plan

Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Viltolarsen (Viltepso)

Prior Authorization Form/Prescription

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

Patient Information

Last Name:	First Name:	Middle:	DOB: ____/____/_____
Address:	City:	State:	Zip:
Daytime Phone:	Evening Phone:	Sex: ☐ Male	☐ Female

Insurance Information (*Attach copies of cards*)

Primary Insurance:		Secondary Insurance:	
ID #	Group #	ID #	Group #
City:	State:	City:	State:

Physician Information

Name:	Specialty:	NPI:	
Address:	City:	State:	Zip:
Phone #:	Secure Fax #:	Office Contact:	

Primary Diagnosis

ICD-10 Code: _____

☐ Duchenne muscular dystrophy (DMD) ☐ Other: _____

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
Viltepso (viltolarsen)				

Clinical Information

***** *Please submit supporting clinical documentation* *****

☐ **INITIAL THERAPY** ☐ **CONTINUATION OF THERAPY;** Therapy start date: _____

1. Has patient had a positive response to the prescribed therapy within the last 30 days?
   ☐ Yes ***Mark all that apply*** ☐ No ☐ Not applicable
   REQUIRED INFORMATION: Must mark all that apply
   a. Ambulatory function with a 6 minute walk test distance (6MWT) ≥ 201 m? ☐ Yes: _____ m ☐ No Date: _____
   b. Ambulatory function with a time-to-stand (TTSTAND) < 10 seconds? ☐ Yes: _____ seconds ☐ No Date: _____
   c. Stable cardiac function with left ventricular ejection fraction (LVEF) ≥ 40%? ☐ Yes: : _____ % ☐ No Date: _____
   d. Stable pulmonary function with predicted forced vital capacity (FVC) ≥ 50%? ☐ Yes : _____ % ☐ No Date: _____
   e. Other: _____
2. Is Viltepso prescribed concurrently with an oral corticosteroid? ☐ Yes ☐ No ☐ No, contraindicated/intolerant
3. Is Viltepso prescribed concurrently with other exon-skipping therapies (e.g. Exondys 51, Vyondys 53)? ☐ Yes ☐ No

Complete this section ONLY if the patient is initiating therapy OR if the patient is new to this health plan:

4. Is therapy prescribed by or in consultation with a neurologist? ☐ Yes ☐ No
5. **If DMD**, is mutation amenable to exon 53 skipping confirmed with genetic testing? ☐ Yes, mutation: _____ - _____ ☐ No
6. Has the patient had an inadequate response (evidence by significant decline in 6MWT, LVEF, or FVC) despite adherent use of an oral corticosteroid (e.g., prednisone, Emflaza™) for ≥ 6 months? ☐ Yes ☐ No ☐ No, contraindicated/intolerant

Complete this section ONLY for indications other than DMD:

7. Has patient tried and failed, or is contraindicated to, accepted standards of care? ☐ Yes ☐ No
   If yes, submit documentation and answer the following:
   a. Please list all previous therapies: _____
   b. Was patient adherent to previously tried therapies? ☐ Yes ☐ No ☐ No, patient intolerant to drug

Physician's Signature: _____ **Date:** _____ ☐ DAW

New PDAC: 08/26/20
Revised:

peach state health plan

Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Viltolarsen (Viltepso)

Prior Authorization Form/Prescription

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

Please continue to page 2

Patient Name: _____ **DOB:** _____

INFORMATION BELOW IS TO BE COMPLETE BY THE HEALTH PLAN/EPS PA STAFF

Authorization Information

Authorization number:	**Decision Due Date:**
J-Code:	**Coverage:** ❑ State excludes ❑ COB (secondary)
Line of Business: ❑ Commercial ❑ Health Insurance Marketplace ❑ Medicaid ❑ Medicare	**Benefit:** ❑ Medical ❑ Pharmacy

Criteria:
❑ Centene Policy
Date Policy last reviewed/approved by plan (we want to be sure we are using the version approved by your plan): _____

❑ State Specific (please include policy)

Medicare only criteria for CY2019 and CY2020:
❑ PART B use LCD or NCD ❑ PART D use the Medicare Part D Viltepso specific criteria